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ABSTRACT
Lysosomal acid lipase (LAL) is a key enzyme controlling neutral lipid metabolic 
signaling in myeloid-derived suppressor cells (MDSCs). MDSCs from LAL-deficient 
(lal−/−) mice directly stimulate cancer cell proliferation. PPARf ligand treatment 
inhibited lal−/− MDSCs stimulation of tumor cell growth and metastasis in vivo, 
and tumor cell proliferation and migration in vitro. In addition, PPARf ligand 
treatment impaired lal−/− MDSCs transendothelial migration, and differentiation 
from lineage-negative cells. The corrective effects of PPARf ligand on lal−/− MDSCs 
functions were mediated by regulating the mammalian target of rapamycin (mTOR) 
pathway, and subsequently blocking MDSCs ROS overproduction. Furthermore, in the 
myeloid-specific dominant-negative PPARf (dnPPARf) overexpression bitransgenic 
mouse model, tumor growth and metastasis were enhanced, and MDSCs from 
these mice stimulated tumor cell proliferation and migration. MDSCs with dnPPARf 
overexpression showed increased transendothelial migration, overactivation of the 
mTOR pathway, and ROS overproduction. These results indicate that PPARf plays 
a critical role in neutral lipid metabolic signaling controlled by LAL, which provides 
a mechanistic basis for clinically targeting MDSCs to reduce the risk of cancer 
proliferation, growth and metastasis.
INTRODUCTION
Lysosomal acid lipase (LAL) hydrolyzes cholesteryl 
esters and triglycerides in the lysosome of cells to generate 
free fatty acids and cholesterol. Genetic ablation of the 
lal gene in mice results in a systemic increase of myeloid 
lineage cells, causing severe inflammation in multiple 
organs [1, 2]. Myeloid-derived suppressor cells (MDSCs), 
with co-expression of myeloid-cell lineage differentiation 
antigen Gr-1 and CD11b in mice, are a heterogeneous 
population of immature myeloid cells at different stages of 
differentiation [3]. We previously reported that the neutral 
lipid metabolic pathway controlled by LAL plays a critical 
role in the development and homeostasis of MDSCs, and 
demonstrated that LAL deficiency leads to the infiltration 
and accumulation of MDSCs in various organs of the mice, 
such as the lung, spleen, thymus, liver and small intestine 
[1, 4]. In addition to immune suppressive function, 
our recent studies showed that LAL-deficient (lal−/−) 
MDSCs possess direct tumor stimulatory function [5]. 
By Affymetrix GeneChip microarray, we have identified 
that many important gene pathways are involved in the 
dysfunctions of lal−/− MDSCs, notably among which, 
peroxisome proliferator-activated receptor-γ (PPARγ)-
regulated gene expression is significantly altered [6].
PPARγ, a member of the nuclear receptor 
superfamily, serves as the receptor of free fatty acid 
derived compounds which arise downstream of LAL 
enzymatic action. After binding to these ligands, 
PPARγ plays an important role in limiting inflammation 
in various tissues by suppressing the expression of 
inflammatory cytokines [7, 8]. Overexpression of 
pro-inflammatory molecules (e.g., apoptosis inhibitor 
6 and matrix metalloproteinase 12) that are negatively 
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regulated by PPARγ has been reported to induce 
chronic inflammation and spontaneous tumor formation 
[9–13]. Our previous study has suggested that LAL 
deficiency causes inactivation of PPARγ by blocking 
ligand generation, which in turn promotes pulmonary 
inflammation and pathogenesis [14]. Furthermore, 
by using the dominant-negative PPARγ (dnPPARγ) 
myeloid-specific overexpression bitransgenic mouse 
model, we found that PPARγ plays a key role in 
controlling pro-inflammatory cytokine synthesis, MDSC 
expansion, immunosuppression, and the development of 
cancer [15].
Since LAL downstream metabolic derivatives 
serve as hormonal ligands for PPARγ, the current study 
examined if PPARγ plays an important role in LAL-
mediated functions in MDSCs. Here, the corrective 
effects of the PPARγ ligand 9-hydroxyoctadecadienoic 
acid (9-HODE) on the neutral lipid metabolic signaling 
controlled by LAL are examined, including effects 
on the development and function of MDSCs, MDSCs 
transendothelial migration, tumor cell proliferation 
and metastasis. The results demonstrate that 9-HODE 
treatment corrected the defects in lal−/− MDSCs via 
effecting the mammalian target of rapamycin (mTOR) 
pathway and by inhibiting overproduction of reactive 
oxygen species (ROS). These findings provide novel 
mechanistic insights into the linkage between lipid 
metabolic signaling and PPARγ in MDSC dysfunction. 
Importantly, these studies reveal the critical role of LAL 
and PPARγ in checking MDSC functions and the potential 
as a therapeutic target to modulate tumor growth and 
spread associated with MDSCs.
RESULTS
PPARγ ligand impaired lal−/− Ly6G+ cell 
stimulation of tumor growth and metastasis 
in vivo
PPARγ inactivation has previously been reported 
to cause inflammation-triggered cell growth and 
emphysema in lal−/− mice, and treatment with the 
PPARγ ligand 9-HODE significantly rescued lal−/− 
pulmonary inflammation and aberrant gene expression 
[14]. lal−/− Ly6G+ MDSCs have recently been found to 
play a role in stimulating tumor growth and metastasis 
[5]. Based on the literature and our own experience, 
the wild type bone marrow is comprised of ~50% 
CD11b+Ly6G+ myeloid precursor cells (with very low 
immunosuppressive function) and very few CD11b+ 
or Ly6G+ single cells. On the other hand, the lal−/− 
bone marrow is comprised of 70% CD11b+Ly6G+ cells 
(with very strong immunosuppression and cancer cell 
stimulation potential). These lal−/− bone marrow cells 
do not further differentiate into more mature myeloid 
cells as wild type cells do [1]. To see whether PPARγ 
inactivation within lal−/− Ly6G+ MDSCs contributes to 
their ability to stimulate tumor cells, freshly isolated 
bone marrow-derived lal+/+ or lal−/− Ly6G+ cells were pre-
treated with 9-HODE or the vehicle, ethanol for 24 h. 
In lal−/− mice, since almost all Ly6G+ cells are positive 
for CD11b, a Ly6G-specific antibody was used for 
purification of Ly6G+CD11b+ cells. To examine tumor 
growth potential in vivo, pre-treated or untreated Ly6G+ 
cells were mixed with untreated B16 melanoma cells, 
and then co-injected subcutaneously into lal+/+ mice. One 
week after the injection, subcutaneous tumors detected 
in the lal−/− Ly6G+ cell-injected mice were significantly 
larger (tumor volume = 63.2 ± 11.7 mm3) than those 
tumors in lal+/+ Ly6G+ cell-injected mice (tumor volume = 
34.6 ± 11.9 mm3, p < 0.01). However, the tumors from 
9-HODE-treated lal−/− Ly6G+ cell-injected mice (tumor 
volume = 36.3 ± 12.4 mm3) were significantly smaller 
when compared with those developed in ethanol-treated 
lal−/− Ly6G+ cell-injected mice (tumor volume = 77.6 ± 
16.4 mm3, p < 0.01) (Figure 1A). The similar effect of 
9-HODE treatment on lal−/− ly6G+ cells to tumor size 
was also observed at 14 and 21 days post-injection 
(Figure 1A). Moreover, when B16 melanoma cells were 
co-injected with C57BL/6 Ly6G+ cells into C57BL/6 
mice, similar results were observed that the tumors from 
9-HODE-treated lal−/− Ly6G+ cell-injected mice were 
significantly smaller than those developed in ethanol-
treated lal−/− Ly6G+ cell-injected mice at 7, 14 and 21 
days post-injection (Figure  1B). As predicted, B16 
melanoma tumor grew larger in C57BL/6 than that in 
FVB/N mice at 14 and 21 days post-injection.
Next, the pre-treated Ly6G+ cells and B16 melanoma 
cells were injected into the tail veins of lal+/+ recipient mice 
to detect metastatic potential. Two weeks after injection, 
less B16 melanoma colonies were observed in the lungs 
of lal+/+ mice that received 9-HODE-treated lal−/− Ly6G+ 
and B16 cell co-injection than those received ethanol-
treated lal−/− Ly6G+ and B16 cell co-injection (Figure 1C). 
9-HODE treatment of lal+/+ ly6G+ cells did not affect B16 
melanoma colonization in the lung (Figure 1C). Sections 
of the lungs showed less neoplastic cells by H&E staining 
and less Ki67 positive cells by IHC staining (Figure 1D). 
These observations suggest that ligand-induced activation 
of the PPARγ pathway in lal−/− Ly6G+ MDSCs impaired 
the ability of these myeloid cells to stimulate tumor 
growth and metastasis.
PPARγ ligand inhibited lal−/− Ly6G+ MDSCs 
stimulation of tumor proliferation and migration 
in vitro
The inhibitory effects of the PPARγ ligand on 
lal−/− Ly6G+ MDSCs stimulation of tumor growth were 
further examined by in vitro co-culture experiments. 
Ligand or vehicle pre-treated lal+/+ or lal−/− Ly6G+ cells 
were co-cultured with B16 melanoma cells for 72 h. 
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Figure 1: PPARγ ligand reverses lal-/- MDSCs stimulation on tumor growth and metastasis in vivo. A. Ly6G+ cells from 
lal+/+ or lal−/− FVB/N mice were pre-treated with ethanol (E) or 20 μmol/L 9-HODE (H) or without treatment (C) for 24 h. Pre-treated 
Ly6G+ cells (6 × 105) and B16 melanoma cells (2 × 105, without any treatment) were mixed, and co-injected subcutaneously into the flank 
region of 3-month old lal+/+ FVB/N mice. n = 8~10. B. Pre-treated C57BL/6 Ly6G+ cells (6 × 105) and B16 melanoma cells (2 × 105) 
were co-injected subcutaneously into the flank region of 3-month old lal+/+ C57BL/6 mice. n = 4. Tumor volume (in cubic millimeters) 
were  measured and statistically analyzed at 7, 14, and 21 days post-injection. For statistical analyses, data were expressed as mean ± SD. 
**P < 0.01, *P < 0.05. C. Pre-treated Ly6G+ cells (2 × 106) and B16 melanoma cells (5 × 105, without any treatment) were intravenously 
co-injected into lal+/+ mice for 2 weeks. Representative lungs and quantitative analysis of the melanoma colony numbers in the lungs are 
shown. Data were expressed as mean ± SD; n = 9~10. **P < 0.01. D. Representative H&E staining and IHC staining with Ki67 antibody 
of the lungs with metastasized melanoma are shown. Original magnification, × 400.
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As shown in Figure 2A, 9-HODE treatment of lal−/− 
Ly6G+ cells significantly decreased proliferation of B16 
melanoma cells upon co-culture, compared with that of 
ethanol-treated lal−/− Ly6G+ cells. When 9-HODE-treated 
lal−/− Ly6G+ cells were co-cultured with Lewis lung cancer 
(LLC) cells, reduced proliferation of LLC cells was also 
observed (Figure 2B). Taken together, these results suggest 
that activation of the PPARγ pathway in lal−/− Ly6G+ cells 
impaired the capacity of these myeloid cells to stimulate 
tumor cell proliferation.
Cytokines secreted by lal−/− Ly6G+ MDSCs have 
been reported to be responsible for mediating their 
Figure 2: PPARγ ligand inhibits lal−/− MDSCs stimulation on tumor proliferation and migration in vitro. Ly6G+ cells 
from lal+/+ or lal−/− mice were pre-treated with ethanol (EtOH) or 20 μmol/L 9-HODE for 24 h. A. Pre-treated Ly6G+ cells (5 × 105) were 
co-cultured with B16 melanoma cells (5 × 103) in vitro for 72 h, and numbers of B16 melanoma cells were counted. n = 4~5. B. Pre-
treated Ly6G+ cells (5 × 105) were co-cultured with LLC cells (1 × 104) in vitro for 72 h, and numbers of LLC cells were counted. n = 4~5. 
C. To see the effect of Ly6G+ cell-secreted cytokines on B16 melanoma cell proliferation, pre-treated Ly6G+ cells (1 × 106) were seeded 
into the upper chamber of transwells, in which B16 melanoma cells (2 × 104) were seeded in the lower chamber. After 72 h, the number 
of B16 melanoma cells was counted. n = 5. D. Left: in vitro migration of B16 melanoma cells with pre-treated Ly6G+ cells at 24 h after 
co-culture in the presence of mitomycin C. The dotted lines define the areas lacking cells. Right: Quantification of distance from one end of 
the wound area to the other end. Data were normalized to B16 melanoma cells co-cultured with control lal+/+ Ly6G+ cells at 0 h. Original 
magnification, × 40. n = 5. For statistical analyses, data were expressed as mean ± SD; **P < 0.01, *P < 0.05.
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stimulatory effects on cancer cell proliferation [5]. To 
examine whether 9-HODE treatment has an effect on 
cytokine-mediated Ly6G+ MDSCs stimulation on cancer 
cell proliferation, transwell studies were performed with 
9-HODE pre-treated Ly6G+ cells seeded in the upper 
chamber and melanoma cells seeded in the lower chamber. 
After 72 h co-culture, the number of B16 melanoma cells 
that were co-cultured with 9-HODE pre-treated lal−/− 
Ly6G+ cells was significantly less (Figure 2C), suggesting 
the ability of lal−/− Ly6G+ cells to promote melanoma cell 
proliferation was impaired by PPARγ ligand treatment.
Because cell migration contributes to metastasis, 
in vitro tumor cell migration assay was analyzed to 
determine whether PPARγ ligand treatment of lal−/− Ly6G+ 
cells influences B16 melanoma cell migration. Melanoma 
cells were treated with mitomycin C to eliminate the 
potential effects of cell proliferation in these assays. As 
shown in Figure 2D, 24 h after co-culture with lal−/− Ly6G+ 
cells, B16 melanoma cells migrated more efficiently into 
the area of an artificial wound area compared with those 
tumor cells co-cultured with lal+/+ Ly6G+ cells. However, 
delayed migration towards the scratch was observed in 
9-HODE pre-treated lal−/− Ly6G+ cells, as revealed by a 
significant increase in the span of the wounded area. These 
results also suggest that activation of the PPARγ pathway 
in lal−/− Ly6G+ cells impaired the stimulatory effects of 
these MSDCs on B16 melanoma cell migration in vitro.
PPARγ ligand decreased lal−/− MDSC 
transendothelial migration capability and 
differentiation from lal−/− Lin- cells
Besides effects on tumor growth and metastasis, 
lal−/− Ly6G+ MDSCs displayed increased transendothelial 
migration capability [16], which likely results in the 
severe infiltration of MDSCs in multiple organs of lal−/− 
mice. To test whether PPARγ inactivation in lal−/− Ly6G+ 
cells plays a role in their increased transendothelial 
migration, transwell assays were performed with 9-HODE 
pre-treated CMFDA-labeled Ly6G+ cells seeded onto an 
endothelial monolayer in the upper chamber of the plates. 
Four hours later, the number of Ly6G+ cells that had 
migrated through to the lower chamber was determined. 
As shown in Figure 3A, there were less Ly6G+ cells in the 
Figure 3: PPARγ ligand decreases lal-/- MDSCs transendothelial migration capacity and differentiation from lal-/-  
Lin- cells. A. Transwell assay was performed to determine MDSCs transmigration across the endothelial monolayer. Ly6G+ cells from 
lal+/+ or lal−/− mice were pre-treated with ethanol (EtOH) or 20 μmol/L 9-HODE for 48 h, and then labeled with CMFDA and seeded onto 
the endothelial monolayer at a density of 2 × 104 cells/well. Four hours after seeding Ly6G+ cells on the EC monolayer, the number of 
Ly6G+ cells that have migrated to the lower chamber was counted. B. Statistical analysis of Ly6G+CD11b+ cells from Lin- cells that were 
treated with ethanol (EtOH) or 10 μmol/L 9-HODE for 5 days by flow cytometry. Data were expressed as mean ± SD; n = 3~4. **P < 0.01, 
*P < 0.05.
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lower chamber when lal−/− Ly6G+ cells were treated with 
9-HODE compared with these cells treated with ethanol, 
suggesting that the PPARγ pathway is involved in Ly6G+ 
cell endothelial transmigration capability.
Abnormal expansion of MDSCs was also observed 
in lal−/− mice, which was due to increased differentiation 
from Lin- cells [1]. PPARγ is known to be expressed in 
bone marrow progenitor cells and play a critical role in 
mesenchymal stem cell differentiation and adipogenesis 
[17–19]. To test the role of PPARγ in this process, bone 
marrow-derived Lin- cells from lal+/+ and lal−/− mice 
were isolated and treated with 9-HODE or ethanol. 
After 5 days of incubation, fewer Ly6G+CD11b+ cells 
were derived from 9-HODE-treated lal−/− Lin- cells 
compared with those with ethanol treatment (Figure 3B), 
suggesting that activation of the PPARγ pathway by 
9-HODE prevented these Lin- cells from differentiating 
into MDSCs.
PPARγ ligand down-regulated mTOR pathway 
activation in lal−/− Ly6G+CD11b+ cells
We have previously reported that the tumor-promoting 
function of lal−/− MDSCs is mediated, at least in part, 
through enhanced activation of the mTOR pathway [5], and 
that the mTOR pathway is involved in the differentiation 
of Lin- cells into Ly6G+CD11b+ cells [20]. To test whether 
PPARγ has an effect on the mTOR pathway, bone marrow 
cells from lal+/+ and lal−/− mice were treated with 9-HODE 
or ethanol. After 2 h of incubation, the expression levels of 
phosphorylated mTOR (pmTOR) and phosphorylated S6 
(pS6) in gated Ly6G+CD11b+ cells were measured by flow 
cytometry analysis. As shown in Figure 4, the increased 
levels of pmTOR and pS6 in lal−/− Ly6G+CD11b+ cells were 
not observed in cells following PPARγ ligand treatment. 
These results suggest that ligand-induced activation of the 
PPARγ pathway in lal−/− Ly6G+CD11b+ cells by 9-HODE 
downregulated mTOR pathway activation.
PPARγ ligand reversed damaged mitochondrial 
membrane potential and suppressed ROS 
production in lal−/− Ly6G+CD11b+ cells
ROS is an important mediator for MDSCs functions, 
and its increase is often associated with mitochondrial 
damage. In lal−/− MDSCs, both damaged mitochondrial 
function and ROS overproduction have been observed, 
and inhibition of the mTOR pathway decreased the ROS 
levels and abnormal mitochondrial membrane potential 
in lal−/− MDSCs [6]. To see whether PPARγ ligand 
treatment corrects these defects, bone marrow cells were 
treated with 9-HODE or ethanol, and ROS levels and 
mitochondrial membrane potentials were measured by 
flow cytometry analysis. As demonstrated in Figure 5A, 
the impaired mitochondrial membrane potential in lal−/− 
Ly6G+ CD11b+ cells was partially recovered with 9-HODE 
treatment compared with that in ethanol-treated cells. 
In addition, 9-HODE treatment suppressed the increased 
ROS production in lal−/− Ly6G+CD11b+ cells (Figure 5B). 
These results suggest that ROS overproduction and 
damaged mitochondrial membrane potential associated 
with lal−/− MDSCs can be corrected by PPARγ ligand 
treatment.
Overexpression of dnPPARγ in myeloid cells 
facilitated tumor growth and metastasis in vivo, 
and tumor proliferation and migration in vitro
To further confirm the critical role of PPARγ in 
myeloid-lineage cells, a doxycycline-inducible c-fms-
rtTA/(tetO)
7
-CMV-dnPPARγ bitransgenic mouse 
model was used, in which a dominant negative PPARγ 
(dnPPARγ) was overexpressed in myeloid cells under the 
control of the c-fms promoter [15]. As we published before 
when the endogenous PPARγ signaling pathway was 
inhibited by overexpression of dnPPARγ in myeloid cells, 
the MDSCs level increased in bone marrow, spleen, blood 
and lung [15]. Here we assess whether the disruption of 
PPARγ function by expression of dnPPARγ in myeloid 
cells has similar effect on tumor cell growth and metastasis 
in vivo and tumor cell proliferation and migration in vitro. 
In tumor growth assessment, B16 melanoma cells were 
subcutaneously injected into the flank region of the 
bitransgenic mice. Figure 6A showed that the tumor 
volume from doxycycline-treated bitransgenic mice was 
significantly increased compared with those in untreated 
mice at 4 weeks post-injection. For the tumor metastasis 
potential, statistical analysis revealed that two weeks 
after intravenous injection of B16 melanoma cells, the 
doxycycline-treated bitransgenic mice showed increased 
number of melanoma colonies in the lungs compared with 
untreated mice (Figure 6B). These results suggest that 
PPARγ inactivation in myeloid cells contributed to the 
increased tumor growth and metastasis.
When bone marrow Ly6G+ cells from doxycycline-
treated bitransgenic mice were co-cultured with B16 
melanoma cells in vitro, increased proliferation of B16 
melanoma cells was observed in comparison with those 
cells from untreated bitransgenic mice (Figure 6C). 
Similarly, proliferation of LLC was significantly 
increased after co-cultured with bone marrow Ly6G+ 
cells from doxycycline-treated bitransgenic mice 
(Figure 6D). Furthermore, the in vitro wound healing 
assay showed accelerated migration towards the scratch 
in B16 melanoma cells co-cultured with bone marrow 
Ly6G+ cells from doxycycline-treated bitransgenic 
mice 24 h after creating the scratch, with a significant 
decrease of distance in the wounding area (Figure 6E). 
In addition, the transendothelial migration capability of 
Ly6G+ cells from doxycycline-treated bitransgenic mice 
was obviously increased as shown in Figure 6F. Taken 
together, these results indicate that PPARγ inactivation in 
Ly6G+ cells facilitated their transendothelial migration, 
and stimulation of tumor cell proliferation and migration.
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Overexpression of dnPPARγ in myeloid cells 
overactivated the mTOR pathway, increased 
ROS production and impaired maintenance of 
mitochondrial membrane potential
To explore the potential mechanisms underlying 
the dysfunctions of MDSCs from doxycycline-treated 
dnPPARγ bitransgenic mice, changes in the mTOR 
pathway were explored. As determined above using 
PPARγ ligands, the pathogenic function of MDSCs could 
be linked to mTOR activation in lal−/− MDSCs. Results 
showed that the phosphorylation levels of mTOR and S6 
in gated doxycycline-treated Ly6G+CD11b+ cells were 
increased significantly compared with those of untreated 
Ly6G+CD11b+ cells, with no statistically significant 
change of mTOR and S6 protein levels (Figure 7A). As 
a consequence, the mitochondrial membrane potential in 
doxycycline-treated Ly6G+CD11b+ cells was impaired 
(Figure 7B). In addition, the ROS production in 
doxycycline-treated Ly6G+CD11b+ cells was significantly 
increased compared with untreated Ly6G+CD11b+ cells 
(Figure 7C). These results support that the PPARγ pathway 
regulates MDSCs functions by modulating mTOR, ROS 
production and mitochondrial membrane potential.
DISCUSSION
Activating PPARγ can prevent cancer development 
and spread in tissues such as colon, breast, prostate 
and lung, while ligand-induced activation of PPARγ 
Figure 4: PPARγ ligand down-regulates the overactivation of the mTOR pathway in lal−/− MDSCs. Bone marrow cells 
from lal+/+ or lal−/− mice were treated with ethanol (EtOH) or 20 μmol/L 9-HODE for 2 h. A. 9-HODE decreased phosphorylation of mTOR 
in gated lal−/− Ly6G+CD11b+ cells. B. 9-HODE decreased phosphorylation of S6 in gated lal−/− Ly6G+CD11b+ cells. Statistical analysis of 
mean fluorescent intensity (MFI) by flow cytometry is shown. Data were expressed as mean ± SD; n = 7. *P < 0.05.
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in cancer cell lines is associated with the induction of 
cell cycle arrest, the increased expression of mRNAs 
and proteins required for terminal differentiation, as 
well as changes in cell morphology that are consistent 
with a differentiated phenotype [21]. Yet understanding 
pathways by which PPARγ contributes to the spread 
and progression of cancer in vivo, including its effects 
on immune cells is less well understood. LAL is a key 
enzyme which functions in the metabolism of neutral 
lipids, and its role in inflammation has been widely 
studied [1, 4, 20, 22]. Genetic ablation of the lal gene 
in mice results in a systemic increases in MDSCs 
and decreases in T cell populations, causing severe 
inflammation and pathogenesis in multiple organs 
[1, 23]. LAL deficiency causes inactivation of PPARγ 
by blocking PPARγ ligand synthesis [14]. The PPARγ 
signaling pathway has recently been reported to play 
a key role in controlling MDSC expansion and T cell 
proliferation [15] . Here, 9-HODE, a PPARγ ligand [24], 
reversed the increased MDSC expansion (Figure 3B) 
and decreased T cell numbers in lal−/− mice (data not 
shown), suggesting that PPARγ signaling is critical in 
regulating LAL-mediated metabolic pathways central to 
immune suppression [15]. Interestingly and importantly, 
our previous [5] and present studies have shown that 
lal−/− MDSCs were able to also overcome potent immune 
rejection and destruction of tumors in allogeneic mouse 
models.
Figure 5: PPARγ ligand reverses the damaged mitochondrial membrane potential and suppresses ROS production 
in lal−/− MDSCs. Bone marrow cells from lal+/+ or lal−/− mice were treated with ethanol (EtOH) or 20 μmol/L 9-HODE for 48 h. 
A. 9-HODE increased the mitochondrial membrane potential in gated lal−/− Ly6G+CD11b+ cells. Left: Representative dot plot analysis of the 
JC-1 red and JC-1 green profiles by flow cytometry. Right: Statistical analysis of the mitochondrial membrane potential in Ly6G+CD11b+ 
cells. B. 9-HODE decreased ROS production in lal−/− Ly6G+CD11b+ cells. Left: Representative analysis of MFI by flow cytometry. Right: 
Statistical analysis of MFI in Ly6G+CD11b+ cells. Data were expressed as mean ± SD; n = 5~6. **P < 0.01, *P < 0.05.
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Figure 6: Overexpression of dnPPARγ in myeloid cells facilitates tumor growth and metastasis in vivo, and tumor 
proliferation and migration in vitro. A. Statistical analysis of tumor volume (in cubic millimeters) at 4 weeks after B16 melanoma 
cells (2 × 105) were subcutaneously injected into doxycycline-treated or untreated c-fmsrtTA/(tetO)7-dnPPARγ bitransgenic mice. n = 5. 
*P < 0.05. B. Quantitative analysis of metastasized B16 melanoma colonies in the lungs of doxycycline-treated or untreated bitransgenic 
mice with intravenous injection of 5 × 105 B16 melanoma cells for 2 weeks. n = 11~12. **P < 0.01. C. B16 melanoma cells (5 × 103) 
were co-cultured with Ly6G+ cells (5 × 105) from doxycycline-treated or untreated bitransgenic mice in vitro for 72 h, and numbers of 
B16 melanoma cells were counted. D. LLC cells (1 × 104) were co-cultured with doxycycline-treated or untreated Ly6G+ cells (5 × 105) 
in vitro for 72 h, and the numbers of LLC cells were counted. E. In vitro migration of B16 melanoma cells with doxycycline-treated or 
untreated Ly6G+ cells at 24 h after co-culture in the presence of mitomycin C. Data were normalized to B16 melanoma cells co-cultured 
with untreated Ly6G+ cells at 0 h. F. Ly6G+ cell transendothelial migration was determined. Data are normalized to untreated Ly6G+ cells. 
In the above experiments (C-F), data were expressed as mean ± SD; n = 4. **P < 0.01.
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In addition to immunosuppression, we have shown 
that lal−/− MDSCs have a second potent effect on tumors, 
by directly stimulating tumor cell proliferation, growth 
and metastasis [5]. B16 melanoma cells grew quickly 
and metastasized massively in allogeneic lal−/− mice, 
yet this effect was suppressed in allogeneic lal+/+ mice 
where immune destruction of the tumor took place. 
However, lal−/− MDSCs facilitated melanoma cells’ 
growth and metastasis in allogeneic lal+/+ mice [5]. In 
our preliminary study, B16 melanoma cells’ metastasis 
was delayed in lal−/− mice pre-treated with PPARγ ligand 
9-HODE. In the present study, activation of the PPARγ 
pathway in lal−/− MDSCs with its ligand 9-HODE not 
only impaired their stimulatory effects on in vivo tumor 
Figure 7: Overexpression of dnPPARγ in myeloid cells overactivates the mTOR pathway, increases ROS production 
and impairs mitochondrial membrane potential. A. The mTOR pathway was overactivated in doxycycline-treated bone marrow 
Ly6G+CD11b+ cells. Statistical analysis of MFI by flow cytometry is shown. Data were expressed as mean ± SD; n = 4~5. **P < 0.01, *P < 0.05. 
B. The mitochondrial membrane potential was impaired in doxycycline-treated bone marrow Ly6G+CD11b+ cells. Left: Representative dot 
plot analysis of the JC-1 red and JC-1 green profiles by flow cytometry. Right: Statistical analysis of the mitochondrial membrane potential 
in Ly6G+CD11b+ cells. C. ROS production was increased in doxycycline-treated Ly6G+CD11b+ cells. Left: Representative analysis of MFI 
by flow cytometry. Right: Statistical analysis of MFI in Ly6G+CD11b+ cells. For statistical analyses, data were expressed as mean ± SD; 
n = 5. **P < 0.01, *P < 0.05.
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growth and metastasis (Figure 1), but also significantly 
retarded the ability of these MSDCs to block in vitro 
tumor cell proliferation and migration (Figure 2). We 
have reported that cytokines, (especially TNFα) secreted 
by lal−/− Ly6G+ cells are, at least in part, responsible for 
mediating stimulatory effects on cancer cells [5]. In the 
present study, 9-HODE inhibited the cytokine-mediated 
stimulatory effects of lal−/− MDSCs on melanoma cell 
proliferation (Figure 2C). Therefore, PPARγ inactivation 
in lal−/− MDSCs represents a major mechanism 
underlying the stimulatory effects of MSDCs on cancer 
cell proliferation and metastasis.
One major manifestation during LAL deficiency 
is systemic MDSCs expansion and dysfunction in 
multiple organs of the mice [1, 2, 14, 22, 25], which 
arises from dysregulated production of hematopoietic 
myeloid progenitor cells in the bone marrow [1]. When 
lal−/− Lin- cells were treated with 9-HODE to activate 
the PPARγ pathway, reduced differentiation of Lin- cells 
into Ly6G+CD11b+ MDSCs was observed (Figure 3B). 
Kaipainen et al showed that PPARγ ligands inhibit primary 
tumor growth and metastasis by targeting endothelial cells 
to inhibit angiogenesis [26]. Abnormal accumulation of 
MDSCs in the lungs of lal−/− mice has been linked to both 
endothelial cells (ECs) and MDSCs [16]. Activation of the 
PPARγ pathway in lal−/− MDSCs with 9-HODE decreased 
the transendothelial migration of MDSCs through the 
EC monolayer (Figure 3A). These results collectively 
indicate that activation of the PPARγ pathway corrects 
lal−/− MDSCs dysfunction and abnormal expansion during 
LAL deficiency.
In addition to inhibition of the PPARγ pathway, 
enhanced activation of the mTOR pathway was associated 
with lal−/− MDSC dysfunction as detected by Affymetrix 
GeneChip microarray and Ingenuity analyses [6]. Thus, 
multiple pathways may contribute to regulate MSDCs 
functions. Studies have shown that the mTOR pathway 
regulates PPARγ activation during adipogenesis by 
targeting the transactivation activity of PPARγ [27, 28]. 
Interaction between mTOR and PPARγ has been reported 
before in hepatocytes [29]. Deficiency of PPARγ in 
chondrocytes resulted in aberrant activation of mTOR 
signaling pathway [30]. The present study shows that the 
mTOR pathway in lal−/− MDSCs is regulated by PPARγ. 
Incubation with 9-HODE not only significantly decreased 
the phosphorylation levels of mTOR and S6, but also 
reduced the overall levels of mTOR and S6 in lal−/− 
MDSCs (Figure 4). ROS production has been reported to 
be one mechanism underlying MDSCs functions [3]. In 
our previous studies, ROS production was increased in 
lal−/− MDSCs with impaired mitochondrial function, which 
mediated the mTOR-regulated lal−/− MDSCs dysfunctions 
[6, 20]. Activation of the PPARγ pathway in lal−/− bone 
marrow cells with its ligand 9-HODE effectively 
improved the mitochondrial function and blocked ROS 
overproduction in lal−/− Ly6G+CD11b+ MDSCs (Figure 5), 
suggesting that ROS overproduction by lal−/− MDSCs is 
controlled by the PPARγ pathway. Therefore, the mTOR-
ROS pathway serves as a potential mechanism to mediate 
the LAL-PPARγ axis in MDSC dysfunctions. Kittler 
et al recently found that PPARγ inhibits cancer cell 
proliferation by a metabolic switch, including suppressing 
pyruvate oxidation and reducing glutathione levels, which 
results in a marked increase of ROS levels, leading to 
rapid hypophosphorylation of retinoblastoma protein 
and cell-cycle rest [31]. Similarly, in a “lal−/− MDSCs-
like cell line”, we have observed an mTOR-controlled 
metabolic switch towards increased glycolysis and ROS 
levels 30. In the current study, with PPARγ ligand treatment 
of lal−/− MDSCs we found these cells displayed reduced 
ROS and were unable to effectively stimulate tumor cell 
proliferation.
The role of the PPARγ pathway in MDSC functions 
was further investigated using an established bitransgenic 
mouse model, in which dnPPARγ was overexpressed 
in myeloid-lineage cells, resulting in blockade of 
endogenous PPARγ function [15]. In this mouse 
model, the function of the receptor of PPARγ pathway 
is impaired rather than the ligand expression which is 
perturbed in lal−/− mouse model. When melanoma cells 
were injected subcutaneously into these mice, larger 
tumor developed in the mice with myeloid-specific 
dnPPARγ overexpression induced by doxycycline than 
non-induced bitransgenic mice (Figure 6A). In addition, 
after intravenous injection of melanoma cells, more 
melanoma developed in the lungs of mice with myeloid-
specific dnPPARγ overexpression (Figure 6B). When 
MDSCs from the mice with myeloid-specific dnPPARγ 
overexpression were co-cultured with B16 melanoma 
cells or LLC cells in vitro, cancer cell proliferation 
was enhanced (Figure 6C and 6D). Moreover, these 
MDSCs facilitated melanoma cell migration (Figure 6E), 
possessed increased transmigration through the EC 
monolayer (Figure 6F), over-activated the mTOR 
pathway, and impaired mitochondrial function and ROS 
overproduction (Figure 7), similar to the characteristics 
observed in lal−/− MDSCs, which showed inactivation of 
the PPARγ pathway.
In conclusion, the PPARγ pathway plays a critical 
role in metabolic signaling controlled by LAL through 
regulating the function of MDSCs. The PPARγ pathway 
served as a novel target to modulate the emergence 
of MDSCs to reduce the risk of cancer progression 
and metastasis. It has been extensively reported that 
PPARγ ligands have a direct inhibitory effect on tumor 
cells [32–40]. But their effect in MDSCs of the tumor 
microenviroment is poorly understood, and should be 
given a special attention. Therefore, PPARγ may impact 
cancer cell proliferation through both direct and indirect 
mechanisms including effects on MSDCs. The study 
outlined here indicates that enhancing PPARγ function 
in MDSCs should prove to be a highly effective strategy 
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in blocking tumor cell growth and spread even in cases 
where tumors may not respond directly to PPARγ ligands. 
Among collection of ligands to PPARγ, those more likely 
to achieve this therapeutic outcome in MDSCs remain to 
be tested.
MATERIALS AND METHODS
Animals and cell lines
Wild-type (lal+/+) and lal−/− mice of the FVB/N 
background were bred in house. c-fms-rtTA/(TetO)
7
-
CMV-dnPPARγ bitransgenic mice of the FVB/N 
background is a previously generated bitransgenic mouse 
model [15]. All scientific protocols involving the use of 
animals have been approved by the Institutional Animal 
Care and Use Committee of Indiana University School 
of Medicine and followed guidelines established by the 
Panel on Euthanasia of the American Veterinary Medical 
Association. Animals were housed under Institutional 
Animal Care and Use Committee-approved conditions in 
a secured animal facility at Indiana University School of 
Medicine.
The murine B16 melanoma cell line, Lewis lung 
carcinoma (LLC) cell line, and murine endothelial cell 
(SVEC) line (purchased from ATCC , Manassas, VA, 
USA) were cultured in DMEM supplemented with 10% 
FBS (Gibco, Grand Island, NY, USA).
PPARγ ligand treatment
For in vitro PPARγ ligand treatment, 9-HODE 
(Cayman Chemical Co., Ann Arbor, MI, USA) was added 
into the culture medium of MDSCs to a final concentration 
of 20 μmol/L for 24 or 48 h. For the study of the effect 
of PPARγ ligand on the mTOR signaling pathway, bone 
marrow cells were treated with 9-HODE (20 μmol/L) 
for 2 h.
Isolation of bone marrow-derived MDSCs
MDSCs were isolated as we previously described 
[5, 6]. Unlike those being classified into monocytic 
and granulocytic MDSCs, almost all lal−/− MDSCs 
are Ly6G+Ly6C+, and almost all lal−/− MDSCs are 
CD11b+Ly6G+ cells. Therefore, to simplify the lal−/− 
MDSCs isolation procedure, Ly6G antibody-coupled 
magnetic beads were used and sufficient to isolate lal−/− 
MDSCs from the lal−/− bone marrow, and equivalent 
control from the wild type bone marrow [1, 2]. Briefly, 
bone marrow cells were isolated from the femurs and tibias 
of mice. Cells were first incubated with biotin-conjugated 
anti-Ly6G antibody at 4°C for 15 min. After washed with 
PBS, cells were incubated with anti-biotin microbeads at 
4°C for another 15 min. Subsequently, cells were subjected 
to magnetic bead sorting according to the manufacturer’s 
instructions (Miltenyi Biotec., Auburn, CA, USA).
Mouse tumor growth and metastasis model
The tumor growth and metastasis model have 
been described recently [5]. MDSCs and B16 melanoma 
cells were collected separately. A pilot study has 
been performed to determine the best ratio between 
MDSCs and B16 melanoma cells. To test the tumor 
growth potential, 6 × 105 pre-treated MDSCs and 
2 × 105 B16 melanoma cells were mixed, centrifuged 
and re-suspended in 100 μL PBS, and then injected 
subcutaneously into the flank region of 3-month old 
recipient lal+/+ mice. Tumor volume (length × width2 
× π/6) was monitored every week for 4 weeks. To test 
the metastasis potential, 2 × 106 pre-treated MDSCs and 
5 × 105 B16 melanoma cells were mixed and incubated 
at 37°C, 5% CO2 for 30 min. After the incubation, 
cells were centrifuged, re-suspended, and injected 
intravenously into 3-month old lal+/+ mice. Two weeks 
after the injection, the mice were sacrificed and the lungs 
were inflated with 4% paraformaldehyde for examination 
of metastasis.
Histology and immunohistochemical staining
The harvested lungs were fixed with 4% 
paraformaldehyde in PBS at 4°C for overnight. After 
fixation and embedding in paraffin, tissue sections 
were cut to 5 μm thick. Hematoxylin and eosin (H&E) 
staining and immunohistochemical (IHC) staining with 
anti-Ki67 antibody were performed by the Histological 
Core Facility, Department of Pathology and Laboratory 
Medicine, Indiana University. Images were taken by 
Olympus microscopy image system (Olympus, Tokyo, 
Japan).
In vitro co-culture of MDSCs and B16 
melanoma cells
Previous study has determined the best ratio 
between MDSCs and B16 melanoma cells [5]. Ethanol 
or 20 μmol/L 9-HODE pre-treated (for 24 h) MDSCs 
(5 × 105) and B16 melanoma cells (5 × 103) were mixed, 
and seeded into a well of 96-well plates in DMEM 
supplemented with 10% FBS. Seventy-two hours later, 
unattached MDSCs were removed by washing with PBS, 
and the number of attached B16 melanoma cells was 
counted. Morphologically, MDSCs are much smaller than 
B16 melanoma cells for exclusion.
In vitro migration assay
In vitro wound healing assay was performed to 
analyze B16 melanoma cell migration as previously 
described [16, 41]. Briefly, B16 melanoma cells 
were seeded at a density of 1.5 × 105 cells/well into 
a 24-well plate and incubated overnight to form a 
confluent monolayer. Scratch was created by scraping 
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the cell monolayer in a straight line with a p200 pipet 
tip. After washing 3 times with DMEM, the medium was 
changed with DMEM containing 10% FBS and 5 μg/mL 
mitomycin C (Sigma-Aldrich, St. Louis, MO, USA), and 
MDSCs pre-treated with 9-HODE or ethanol for 24 h 
were added onto B16 melanoma cell monolayer at a 
density of 1 × 106 cells/well. Images were taken at 0 and 
24 h after creating the scratch. Migration was estimated 
by measuring the distances from one side of scratch to 
the other side using Image Pro-Plus software (Media 
Cybernetics, Rockville, MD, USA).
Transwell assay
Transwell assay was used to determine MDSC 
transendothelial migration [16]. SVECs were added to 
the upper chamber of 24-well 8.0-μm-pore Transwell 
plates (Corning, Corning, NY, USA), and incubated at 
37°C, 5% CO2 for 48 h to form an EC monolayer. The 
supernatant was then removed, and CellTrackerTM 
Green 5-Chloromethylfluorescein Diacetate (CMFDA) 
(Invitrogen, Grand Island, NY, USA)-labeled MDSCs 
(2 × 104 cells in 200 μL media) were added to the upper 
well. After 4 h, transendothelial migration of MDSCs 
was determined by counting their numbers in the lower 
chamber under 5 random microscopic fields.
To observe the effect of MDSCs-secreted cytokines 
on melanoma cell proliferation, transwell assay was 
performed with 0.4-μm-pore 6.5-mm diameter Transwell 
plates (Corning) to separate MDSCs and B16 melanoma 
cells. One million pre-treated MDSCs in 200 μL media 
were seeded into the upper chamber of the plates, while 
2 × 104 melanoma cells in 500 μL media were placed in 
the lower chamber. After 72 hours’ culture, the transwells 
were removed, and the number of B16 melanoma cells in 
the lower chamber was counted.
Isolation of bone marrow lineage-negative cells
Lineage-negative (Lin-) cells were isolated from 
the bone marrow by removing blood lineage marker-
positive cells with an immunomagnetic microbead 
technique as we previously described [20]. Briefly, 
bone marrow cells were first incubated with a cocktail 
of biotin-conjugated antibodies against lineage specific 
antigens: CD11b, GR-1, B220, TER-119, and CD3ε 
(Mouse Lineage Panel Kit, BD Pharmingen, San Diego, 
CA, USA) at 4°C for 15 min. After washed with PBS, 
cells were then incubated with anti-biotin microbeads 
at 4°C for another 15 min. Subsequently, cells were 
subjected to magnetic bead sorting according to the 
manufacturer’s instructions (Miltenyi Biotec.). The 
resulting Lin- cells were cultured in RPMI1640 with 
10% FBS. Five days later, Ly6G+CD11b+ cells derived 
from Lin- cells were analyzed by flow cytometry 
analysis.
ROS and mitochondrial membrane potential 
measurement
The reactive oxygen species (ROS) level and 
mitochondrial membrane potential in MDSCs was 
measured by flow cytometry as we previously described 
[20]. Briefly, bone marrow cells were first treated with or 
without 20 μmol/L 9-HODE or ethanol for 2 days. For 
ROS level detection, cells were harvested, washed, and 
stained with 2′, 7′-dichlorofluorescein diacetate (2 μmol/L, 
Invitrogen), allophycocyanin cy7-conjugated anti-Ly6G 
Ab, and phycoerythrin cy7-conjugated anti-CD11b Ab 
(eBioscience) at 37°C for 15 min. After PBS wash, the 
ROS level in Ly6G+CD11b+ cells was analyzed using a 
LSRII machine (BD Biosciences).
For mitochondrial membrane potential measurement, 
cells were stained with the fluorescent dye JC-1 (2 μmol/L, 
Molecular Probes, Eugene, OR, USA), allophycocyanin 
cy7-conjugated anti-Ly6G antibody, and phycoerythrin 
cy7-conjugated anti-CD11b antibody (eBioscience) at 
37°C for 15 min, and then analyzed for phycoerythrin 
(JC-1 red) and fluorescein isothiocyanate (JC-1 
green) fluorescent cells in Ly6G+CD11b+ cells by flow 
cytometry. Cells treated with 50 μmol/L carbonyl cyanide 
3-chlorophenylhydrazone for 5 min were served as a 
fluorescein isothiocyanate-positive control.
Flow cytometry analysis
Single cells from the bone marrow of 5-month-old 
lal+/+ and lal−/− mice were prepared as previously described 
[9]. After 20 μmol/L 9-HODE treatment for 2 h, cells were 
harvested, and labeled with anti-Ly6G and CD11b cell 
surface antibody (eBioscience) at 4°C for 15 min. Cells 
were then fixed and permeabilized using BD Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences) 
according to the manufacturer’s instructions, and 
incubated with Alexa Fluor 647-conjugated anti-mTOR 
antibody, Alexa Fluor 488-conjugated anti-S6 antibody, 
Alexa Fluor 488-conjugated anti-pS6 (Ser235/236) 
antibody, and rabbit anti-pmTOR (Ser2448) antibody 
(Cell Signaling Technology, Beverly, MA, USA) at 4°C 
overnight. For anti-pmTOR antibody staining, cells were 
incubated with Alexa Fluor 647-conjugated anti-rabbit IgG 
in the following day. Cells were washed and ready for flow 
cytometry analysis. Mean fluorescence intensities of the 
proteins in the gated Ly6G+CD11b+ area were analyzed. 
For flow cytometry analysis, ≥ 10,000 cells were acquired 
and scored using a LSRII machine (BD Biosciences). Data 
were processed using the CellQuest software program (BD 
Biosciences).
Statistics
Data were expressed as mean ± SD. Differences 
between two treatment groups were compared by 
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Student’s t-test. When more than two groups were 
compared, one-way ANOVA with post-hoc Newman-
Keul’s multiple comparison test was used. Results were 
considered statistically significant when P < 0.05. All 
analyses were performed with GraphPad Prism 5.0 
(GraphPad, San Diego, CA, USA).
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